To address these questions, we proposed the hypothesis that in a gradient concentration of L-ascorbic acid with different expression levels of SVCT-2, the anti-cancer effects of L-ascorbic acid change to hormetic proliferation when insufficient ROS are generated. The gene discussed is SLC23A2; the disease is cancer.